satraplatin

Known as: (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum, bis-acetatoamminedichlorocyclohexylamine platinum(IV), platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43) 
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
05101519992017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
BACKGROUND The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
Satraplatin acts as a potent inhibitor of proliferation in castration-resistant prostate cancer, yet the basic and molecular… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin’s… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
The goal of this study was to identify molecular determinants of sensitivity and resistance to JM118, the active metabolite of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
Satraplatin is a novel oral platinum (IV) complex that shows activity against hormone-refractory prostate cancer (HRPC) in… (More)
Is this relevant?
2005
2005
Background. Satraplatin is thought to require reduction to a reactive Pt(II) complex (JM118) before exerting chemotherapeutic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
Satraplatin is an orally bioavailable platinum analog that has activity in prostate cancer. JM118 is the most abundant species… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
BACKGROUND Satraplatin (JM216; bis-acetatoammine-dichlorocyclohexylamine platinum (IV)) is a platinum (Pt) complex developed in… (More)
Is this relevant?